Nanostics Inc. products

Our lead product, ClarityDx Prostate® is designed to be a highly accurate test to assist in diagnosing clinically significant prostate cancer and improve prostate healthcare decisions. Validation of ClarityDX Prostate® is ongoing in a 2800 patient clinical study designed to meet regulatory approval.

Our core technology ClarityDX® can: Identify biomarkers expressed by diseased cells/tissues. Indicate if treatment is needed. Predict treatment response and resistance. Stratify disease stage. Identify disease recurrence.